Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Alginic acid (DB13518)

Also known as: Reflux Disease, Gastro-Esophageal / Oesophageal Reflux / Gastroesophageal Refluxdisease / Gastrooesophageal reflux disease / Gastro-esophageal Reflux Disease / GERD / Esophageal Reflux / Gastroesophageal Reflux Disease (GERD) / Gastro Oesophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD (Gastroesophageal Reflux Disease) / Gastro-Oesophageal Reflux Disease / GERD - Gastro-Esophageal Reflux Disease / GERD Gastroesophageal Reflux Disease / Gastroesophageal Reflux Disease / Gastro Esophageal Reflux Disease / Gastrooesophageal reflux / Gastroesophageal reflux / Acid reflux (finding) / GORD / Gastro-esophageal reflux disease without esophagitis / Gastroesophageal reflux disease (disorder) / Esophageal reflux finding (finding)

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02623062Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief StudyTreatment
NCT01878526Gastroesophageal Reflux Treatment in SclerodermaTreatment
NCT01872897Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD PatientsTreatment
NCT01869491Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief StudyTreatment
NCT01338077Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux DiseaseTreatment